Kiran Mazumdar-Shaw

2 posts

Spray and pray – the COVID-19 version

Sep 2, 2020 2 min read

Kiran Mazumdar-Shaw is the head of Biocon, a company headquartered in Bengaluru and which has repurposed a drug called itolizumab – already approved to help manage severe chronic psoriasis in differen…

The matter of a journal's reputation

Aug 8, 2020 5 min read

Analysis Science Biocon Björn Brembs COVID-19 cytokine release syndrome Dinesh Thakur Drug Controller General of India Itolizumab Jammi Nagaraj Rao journal impact factor Kiran Mazumdar-Shaw Newslaundry phase II clinical trials phase III clinical trials prestige journals prestigious journals reputed journals Seema Ahuja Sundar Ramanan The Telegraph

Apparently (and surprisingly) The Telegraph didn’t allow Dinesh Thakur to respond to an article by Biocon employee Sundar Ramanan, in which Ramanan deems Thakur’s article about the claims to efficacy…